Tectonic Therapeutic, Inc.
Close on Oct 19, 2026
- Market cap
- $401.09M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | $-0.93 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | After market close | – | $-0.84 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | $-4.34 | – |
| Q1 FY2024 Ended Mar 31, 2024 | Jun 20, 2024 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | Before market open | – | $-0.57 | – |
Press releases
Announcements Tectonic Therapeutic filed with the SEC
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Anti-Angiogenic Therapy for HHT and Other Bleeding Disorders FEBRUARY 24, 2026 Exhibit 99.2
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Hemodynamic Trial O c t o b e r 2025
Other events · EX-99.1 to Form 8-K
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary
Other events · EX-99.2 to Form 8-K
Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapies to Reach Large Untapped Market Opportunities Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Tectonic Announces $185 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of our product candidates, including the ongoing Phase 1b and Phase 2 clinical trial for TX45, in Group 2 Pulmonary Hypertension; the
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program
Regulation FD disclosure · EX-99.1 to Form 8-K
of Novel, Class Leading GPCR-Targeted Therapies S e p t e m b e r 2 0 2 4
Regulation FD disclosure · EX-99.2 to Form 8-K
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
of Novel, Class Leading GPCR-Targeted Therapies J u l y 2 0 2 4
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Transforming and Innovating the Discovery and Development of Novel, Class Leading GPCR-Targeted TherapiesJ
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
TECTONIC MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Unaudited Interim Condensed Consolidated Financial Statements for the Three Months ended
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Other events · EX-99.3 to Form 8-K
Therapies J A N U A R Y 2 0 2 4
Regulation FD disclosure · EX-99.1 to Form 8-K
AVROBIO and Tectonic Therapeutic Announce Merger
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AVROBIO to Explore Strategic Alternatives
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA FINANCIAL INFORMATION
Agreement terminated · Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AVROBIO Completes Sale of Cystinosis Gene Therapy Program
Agreement terminated · Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
Material agreement · Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of
Regulation FD disclosure · EX-99.1 to Form 8-K
Disclaimer 2 This presentation has been prepared by AVROBIO, Inc.
Regulation FD disclosure · EX-99.2 to Form 8-K
AVROBIO Reports First Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Current CFO Erik Ostrowski named interim CEO, replacing Founding President and CEO Geoff MacKay
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K